The Remicade Biosimilar Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Remicade Biosimilar Market:
https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report
According to The Business Research Company’s Remicade Biosimilar Global Market Report 2024, The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.2 billion in 2023 to $3.99 billion in 2024 at a compound annual growth rate (CAGR) of 24.4%. The growth in the historic period can be attributed to introduction of remicade (infliximab), biotechnology advancements, biologics patent expiry, regulatory pathway establishment, healthcare cost pressures.
The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $9.1 billion in 2028 at a compound annual growth rate (CAGR) of 22.9%. The growth in the forecast period can be attributed to patent expirations, rising demand for cost-effective therapies, biosimilar pipeline development, reimbursement policies, market consolidation. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence.
The rise in the incidence of autoimmune diseases is expected to propel the growth of the remicade biosimilar market going forward. Autoimmune diseases are disorders in which the immune system mistakenly attacks and damages the body's tissues and organs. Remicade biosimilars are used in treating autoimmune diseases by providing an effective therapeutic option to manage the symptoms and reduce inflammation associated with these. For instance, in October 2021, according to the reports shared by the City University of London, a UK-based public university, in the UK, 7%, or 4 million people, were suffering from autoimmune diseases by 2021, and over 80 autoimmune illnesses were identified with increasing prevalence annually by 3–9%. Furthermore, in July 2021, according to the Cleveland Clinic, a US-based, non-profit academic medical center, autoimmune diseases affected 1 in 15 people, with 1.4 million individuals having Crohn's disease or ulcerative colitis, while 1 million people had lupus in 2021. Therefore, the rise in the incidence of autoimmune diseases is driving the growth of the Remicade biosimilar market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp
The remicade biosimilar market covered in this report is segmented –
1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases
Product innovation is a key trend gaining popularity in the Remicade biosimilar market. Major companies operating in the Remicade biosimilar market are developing innovative products to sustain their position in the market. For instance, in January 2023, Amgen Inc, a US-based biotechnology company, launched Amjevita, a biosimilar version of AbbVie's Humira, in the US, designed to be as safe and effective as the original drug. Amjevita is the first biosimilar to Humira and is expected to compete with Humira for market share. It is a biological drug used to treat various autoimmune diseases, including rheumatoid arthritis and Crohn's disease. It is one of the most expensive drugs in the world, generating billions of dollars in sales for AbbVie each year. Amjevita is expected to cost significantly less. In addition to saving money, Amjevita can also offer patients more treatment options.
The remicade biosimilar market report table of contents includes:
1. Executive Summary
2. Remicade Biosimilar Market Characteristics
3.Remicade Biosimilar Market Trends And Strategies
4.Remicade Biosimilar market analysis
5.Remicade Biosimilar Market Size And Growth
6.Remicade Biosimilar Segmentation
7.Remicade Biosimilar Regional And Country Analysis
.
.
.
27.Remicade Biosimilar Competitive Landscape And Company Profiles
28. Remicade Biosimilar Key Mergers And Acquisitions
29.Remicade Biosimilar Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- AbbVie Inc.
- Novartis AG
- Amgen Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Biogen Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Global Biosimilar of Remicade Scope and Market SizeBiosimilar of Remicade market is segmented by company, region (country), by Type, and by Application.
Players, stakeholders, and other participants in the global Biosimilar of Remicade market will be able to gain the upper hand as they use the report as a powerful resource.
The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-china-biosimilar-of-remicade-2021-2027-502 Segment by Type Monoclonal AntibodiesInterferonErythropoietinInsulinVaccinesOther Segment by Application TumorDiabetesCardiovascularHemophiliaOther By Region North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of AsiaLatin AmericaMexicoBrazilRest of Latin AmericaMiddle East & AfricaTurkeySaudi ArabiaUAERest of MEA By Company RocheAmgenAbbVieSanofi-AventisJohnson & JohnsonPfizerNovo NordiskEli LillyNovartisMerck3sbioChangchun High TechCP GuojianBiotechGelgenInnoventDong BaoGanleeUnited LaboratoriesGet the Complete Report & TOC @ https://www.grandresearchstore.com/ict-and-media/global-china-biosimilar-of-remicade-2021-2027-502Table of content1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Biosimilar of Remicade Market Size Growth Rate by Type: 2016 VS 2021 VS 20271.2.2 Monoclonal Antibodies1.2.3 Interferon1.2.4 Erythropoietin1.2.5 Insulin1.2.6 Vaccines1.2.7 Other1.3 Market by Application1.3.1 Global Biosimilar of Remicade Market Share by Application: 2016 VS 2021 VS 20271.3.2 Tumor1.3.3 Diabetes1.3.4 Cardiovascular1.3.5 Hemophilia1.3.6 Other1.4 Study Objectives1.5 Years Considered2 Global Growth Trends2.1 Global Biosimilar of Remicade Market Perspective (2016-2027)2.2 Biosimilar of Remicade Growth Trends by Regions2.2.1 Biosimilar of Remicade Market Size by Regions: 2016 VS 2021 VS 20272.2.2 Biosimilar of Remicade Historic Market Share by Regions (2016-2021)2.2.3 Biosimilar of Remicade Forecasted Market Size by Regions (2022-2027)2.3 Biosimilar of Remicade Industry Dynamic2.3.1 Biosimilar of Remicade Market Trends2.3.2 Biosimilar of Remicade Market Drivers2.3.3 Biosimilar of Remicade Market Challenges2.3.4 Biosimilar of Remicade Market Restraints3 Competition Landscape by Key Players3.1 Global Top Biosimilar of Remicade Players by Revenue3.1.1 Global Top Biosimilar of Remicade Players by Revenue (2016-2021)3.1.2CONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
The Remicade Biosimilar Market Research Report Forecast is a valuable source of insightful data for business strategists.
It provides the industry overview with recent trends, size, share, growth analysis, historical, futuristic data, revenue, demand and strategic development.The broad remicade biosimilar market has been sub-grouped into disease indication.
The report studies these subsets with respect to the geographical segmentation.
The strategists can gain a detailed insight and devise appropriate strategies to target specific market.
This detail will lead to a focused approach leading to identification of better opportunities.Request a FREE Sample Copy of Remicade Biosimilar Market Report with Full TOC At: https://www.valuemarketresearch.com/contact/remicade-biosimilar-market/download-sampleBy Disease IndicationUlcerative ColitisRheumatoid ArthritisAnkylosing SpondylitisCrohn’s DiseasePsoriatic ArthritisPlaque PsoriasisThe report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the remicade biosimilar market include Alvogen, Celltrion, Janssen Biotech, Inc., Merck and Company, Inc., Napp Pharmaceuticals, Nippon Kayaku and Pfizer, Inc. among others.
